Bluebird bio Inc, which is developing gene therapies for cancer and rare diseases, is partnering with Regeneron Pharmaceuticals Inc to discover, develop and commercialise new therapies for cancer. The deal includes a $100 million investment by Regeneron in bluebird stock.
